LncRNA Information | ||||||
---|---|---|---|---|---|---|
ID | EL1082 | Name | PRAL | Aliases | N/A | |
Species | Homo sapiens | Chromosome | N/A | Start site | N/A | |
End site | N/A | Chain | N/A | Exon NO. | N/A | |
Assembly | N/A | Class | N/A | NCBI accession | N/A | |
Ensembl | N/A | Sequence | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
hepatocelluar carcinoma | qPCR, Western blot etc. | hepatocellular carcinoma tissues | down-regulated | interaction | We found that lncRNA-PRAL could inhibit HCC growth and induce apoptosis in vivo and in vitro through p53. Subsequent investigations indicated that the three stem-loop motifs at the 5' end of lncRNA-PRAL facilitated the combination of HSP90 and p53, and thus competitively inhibited the MDM2-dependent p53 ubiquitination, resulting in the enhanced p53 stability. Additionally, in vivo lncRNA-PRAL delivery efficiently reduced the intrinsic tumors, indicating its potential therapeutic application. | 26663434 | Lnc2Cancer | ||
Interaction | |||||||||
---|---|---|---|---|---|---|---|---|---|
Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
p53 | RNA-Protein | regulation | The three stem-loop motifs at the 5' end of lncRNA-PRAL facilitated the combination of HSP90 and p53 and thus competitively inhibited MDM2-dependent p53 ubiquitination, resulting in enhanced p53 stability. | 26663434 | |||||